Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Feb 8:15:1332418.
doi: 10.3389/fendo.2024.1332418. eCollection 2024.

Glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system 2-year prospective, observational, two-center study

Sebastian Seget  1 , Agata Chobot  2 , Mateusz Tarasiewicz  1 , Anna Bielawska  1 , Ewa Rusak  1 , Agnieszka Ochab  2 , Joanna Polanska  3 , Przemysława Jarosz-Chobot  1
Affiliations
Observational Study

Glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system 2-year prospective, observational, two-center study

Sebastian Seget et al. Front Endocrinol (Lausanne). .

Abstract

Background and aims: MiniMed 780G is the first Advanced Hybrid Closed Loop (AHCL) system in Poland, approved in the EU in 2020. To date, observations of glycemic control up to 12 months have been published. This study aimed to analyze glycemic control and anthropometric parameters in children and adolescents with type 1 diabetes (T1D) after two years of using the AHCL system.

Materials and methods: We prospectively collected anthropometric data, pump, and continuous glucose records of fifty T1D children (9.9 ± 2.4 years, 24 (48%) boys, T1D for 3.9 ± 2.56 years) using an AHCL system. We compared the two-week AHCL records obtained after AHCL enrollment with data 6, 12, and 24 months after starting AHCL.

Results: Time in range (70-180 mg/dl) and BMI z-score did not change during the 2 years of observation (p>0.05). The percentage of autocorrection in total daily insulin increased significantly (p<0.005).

Conclusion: Glycemic control in the investigated group of children with T1D treated with the AHCL system for 2 years remained stable. Children in this group maintained weight and optimal metabolic control, most likely due to autocorrection boluses.

Keywords: BMI; advanced hybrid closed-loop system; body mass index; children; time in range; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

PJ-C has received speaker honoraria from Medtronic, Dexcom, Abbott, Ypsomed, and Roche, was a member of the advisory boards for Medtronic and Abbott, and received research support from Medtronic. SS has received speaker honoraria from Medtronic and Ypsomed. The remaining authors declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The percentage of glucose measurements in the 70-180 mg/dl range during the observation time. The left panel presents the box plots independently calculated for each observation time point, while the right panel shows the time series for each patient.
Figure 2
Figure 2
The boxplots for the Total Dose of Insulin (TDI) per kg (left panel) and the proportion of the autocorrection in TDI during the time of observation (right panel).
Figure 3
Figure 3
The boxplot presenting the changes in time for the percentage of the bolus insulin.
Figure 4
Figure 4
BMI z-score in time. The left panel presents the box plots independently calculated for each observation time point, while the right panel shows the time series for each patient.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sherr JL, Schoelwer M, Dos Santos TJ, Reddy L, Biester T, Galderisi A, et al. . ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatr Diabetes (2022) 23(8):1406–31. doi: 10.1111/pedi.13421 - DOI - PubMed
    1. Medtronic: MiniMed 780G. System User Guide. Available at: https://www.medtronic-diabetes.co.uk/sites/uk/medtronic-diabetes.co.uk/f... (Accessed January 24, 2022).
    1. Seget S, Rusak E, Polanska J, Jarosz-Chobot P. Prospective open-label, single-arm, single-center follow-up study of the application of the advanced hybrid closed loop system in well-controlled children and adolescents with type 1 diabetes. Diabetes Technol Ther (2022) 24(11):824–31. doi: 10.1089/dia.2022.0148 - DOI - PMC - PubMed
    1. Matejko B, Juza A, Kieć-Wilk B, Cyranka K, Krzyżowska S, Chen X, et al. . Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to miniMed 780G advanced hybrid closed-loop system: A two-center, randomized, controlled study. Diabetes Care (2022) 45(11):2628–35. doi: 10.2337/dc22-0470 - DOI - PMC - PubMed
    1. Pulkkinen MA, Varimo TJ, Hakonen ET, Harsunen MH, Hyvönen ME, Janér JN, et al. . MiniMed 780G™ in 2- to 6-year-old children: safety and clinical outcomes after the first 12 weeks. Diabetes Technol Ther (2023) 25(2):100–7. doi: 10.1089/dia.2022.0313 - DOI - PubMed

Publication types